We are a leading China-based ophthalmic company with an innovative and diverse portfolio, with products from pre-clinical to commercial stage.
Employees: 51-200
Total raised: $100M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.03.2021 | Series B | $100M | - |
Mentions in press and media 21
| Date | Title | Description |
| 04.07.2022 | Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia | This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs in China. ARVN003 is expected to be the first approved d... |
| 04.04.2022 | Rail Vision Ltd. Announces Closing of $15.6 Million Initial Public Offering | Ra’anana, Israel, April 04, 2022 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (the “Company”) (Nasdaq: RVSN), a development stage technology company that is seeking to revolutionize railway safety and the data-related market, today announced the cl... |
| 22.12.2021 | Medical Data Vision Co., Ltd. announces an Equity Buyback for 800,000 shares, representing 2.05% for ¥1,000 million. | Medical Data Vision Co., Ltd. (TSE:3902) announces a share repurchase program. Under the program, the company will repurchase up to 800,000 shares, representing 2.05% of its issued share capital, for ¥1,000 million. The purpose of the progr... |
| 22.11.2021 | Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME) | First-in-class SCS Microinjection therapy First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis U.S. FDA approved for treatment of macular edema associated with uv... |
| 22.11.2021 | Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME) | First-in-class SCS Microinjection therapy First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis U.S. FDA approved for treatment of macular edema associated with uv... |
| 17.09.2021 | Arctic Vision : Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal | SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to incl... |
| 17.09.2021 | Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal | SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to incl... |
| 16.09.2021 | Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal | |
| 03.09.2021 | Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment | SHANGHAI, Sept. 3, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, today announced the clearance of the Investigational New Drug (IND) application... |
| 02.09.2021 | Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment |
Show more